Table 1.
Body composition and basal metabolic variables
| Placebo | NMN | RM-ANOVA | |||||
|---|---|---|---|---|---|---|---|
| Before | After | Before | After | Pgroup | Ptime | Pgroup × time | |
| Age (yrs) | 61±5 | - | 62±4 | - | - | - | - |
| Body weight (kg) | 87 ± 3 | 87 ± 3 | 89 ± 4 | 89 ± 4 | 0.764 | 0.917 | 0.941 |
| Body mass index (kg/m2) | 33.4 ± 1.0 | 33.3 ± 0.9 | 33.7 ± 1.4 | 33.8 ± 1.5 | 0.928 | 0.917 | 0.941 |
| Fat mass (kg) | 40.3 ± 2.0 | 39.9 ± 2.0 | 42.8 ± 2.9 | 42.9 ± 3.0 | 0.547 | 0.672 | 0.702 |
| Fat free mass (kg) | 45.6 ± 0.9 | 46.1 ± 0.7 | 44.8 ± 1.2 | 45.5 ± 1.3 | 0.654 | 0.011 | 0.846 |
| Intrahepatic triglyceride content (%) | 14.8 ± 2.0 | 15.7 ± 2.5 | 6.3 ± 1.2 | 6.8 ± 1.3 | 0.003 | 0.385 | 0.461 |
| Intra-abdominal adipose tissue volume (cm3) | 1,576 ± 71 | 1,669 ± 95 | 1,492 ± 213 | 1,504 ± 214 | 0.265 | 0.180 | 0.186 |
| Systolic blood pressure (mmHg) | 128 ± 4 | 131 ± 4 | 126 ± 5 | 125 ± 5 | 0.089 | 0.813 | 0.686 |
| Diastolic blood pressure (mmHg) | 73 ± 3 | 77 ± 3 | 73 ± 3 | 75 ± 3 | 0.832 | 0.286 | 0.701 |
| HbA1C (%) | 5.5 ± 0.1 | 5.5 ± 0.1 | 5.7 ± 0.1 | 5.5 ± 0.1 | 0.407 | 0.008 | 0.396 |
| Glucose (mmol/L) | 5.7 ± 0.2 | 5.6 ± 0.2 | 5.7 ± 0.1 | 5.6 ± 0.2 | 0.906 | 0.379 | 0.836 |
| Insulin (μU/mL) | 16.7 ± 2.0 | 17.2 ± 2.5 | 13.6 ± 1.9 | 15.8 ± 2.7 | 0.400 | 0.122 | 0.335 |
| Free fatty acids (g/L) | 0.198 ± 0.018 | 0.183 ± 0.011 | 0.192 ± 0.014 | 0.193 ± 0.015 | 0.973 | 0.493 | 0.492 |
| Triglyceride (mmol/L) | 1.63 ± 0.22 | 1.48 ± 0.23 | 1.39 ± 0.25 | 1.26 ± 0.18 | 0.289 | 0.107 | 0.554 |
| HDL-cholesterol (mmol/L) | 1.28 ± 0.07 | 1.34 ± 0.07 | 1.25 ± 0.10 | 1.30 ± 0.10 | 0.804 | 0.071 | 0.930 |
| High molecular weight adiponectin (μg/mL) | 4.02 ± 0.53 | 3.93 ± 0.51 | 3.90 ± 0.49 | 3.86 ± 0.52 | 0.900 | 0.564 | 0.843 |
| Leptin (ng/mL) | 83.5 ± 8.1 | 82.4 ± 6.8 | 88.1 ± 6.7 | 88.5 ± 7.3 | 0.589 | 0.916 | 0.811 |
| Basal glucose Ra (μmol/kg FFM/min) | 15.5 ± 0.4 | 15.4 ± 0.4 | 15.7 ± 0.4 | 16.1 ± 0.5 | 0.469 | 0.459 | 0.311 |
| Basal palmitate Ra (μmol/kg FFM/min) | 2.66 ± 0.29 | 2.23 ± 0.17 | 2.28 ± 0.21 | 2.21 ± 0.18 | 0.455 | 0.098 | 0.247 |
Values are means ± SEM. Metabolic variables were measured before and after placebo (n=12) or NMN (n=13) treatment. A two-way mixed model ANOVA was used to evaluate the effect of NMN supplementation on each outcome. The effect of NMN on these variables was not different from placebo. Abbreviation: FFM, fat-free mass